Can B Past Earnings Performance

Past criteria checks 0/6

Can B's earnings have been declining at an average annual rate of -23.5%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 34.8% per year.

Key information

-23.5%

Earnings growth rate

58.9%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate34.8%
Return on equity-4,932.0%
Net Margin-443.0%
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Can B makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:CANB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 232-1150
30 Jun 235-14110
31 Mar 236-13120
31 Dec 227-15140
30 Sep 228-16150
30 Jun 227-12110
31 Mar 226-13110
31 Dec 215-12100
30 Sep 213-13140
30 Jun 212-11110
31 Mar 211-1090
31 Dec 202-990
30 Sep 202-670
30 Jun 202-670
31 Mar 202-670
31 Dec 192-660
30 Sep 192-350
30 Jun 192-650
31 Mar 191-640
31 Dec 181-430
30 Sep 180-620
30 Jun 180-220
31 Mar 180-210
31 Dec 170-210
30 Sep 170-100
30 Jun 170-100
31 Mar 170000
31 Dec 160-100
30 Sep 160-100
30 Jun 160-110
31 Mar 160-110
31 Dec 150-420
30 Sep 150-310
31 Dec 140000
31 Dec 130000

Quality Earnings: CANB is currently unprofitable.

Growing Profit Margin: CANB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CANB is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare CANB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CANB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: CANB has a negative Return on Equity (-4932.03%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.